Appropriate DESCOVY FOR PrEP® Candidates
INDICATION & LIMITATION OF USE

DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Many patients could benefit from starting a PrEP medication—why wait for them to ask for it?

In one survey (n=280), PCPs reported that 60% of their PrEP-related discussions were initiated by patients1

There are several reasons why eligible patients may not already be using a PrEP medication. Some common barriers to PrEP use include2

Slanted icon of blue pill with 225 imprint

Low awareness of PrEP options

Underestimation of HIV risk

Anxiety about side effects

What should you look for to help identify those at risk for HIV?

HIV risk factors can be behavioral, biological, or epidemiologic, and may include3

Past or current STIs

Sexual activity in a high-prevalence area or social network

Condomless sex

Self-identified HIV risk

Sexual partners of unknown HIV-1 viremic status

Uncover HIV risk by starting a dialogue with patients about

STI history4

"Have you or your partner(s) ever had an STI?"

Gaps in PrEP use5

“Have you ever been on a PrEP medication before?”

In a real-world study (N=986),* seroconversions among patients who stopped their PrEP medication saw a 7.5-fold increase compared with patients who continued using their PrEP regimen

HIV testing habits6

"Do you tend to get tested for HIV regularly or just when you think you may have been exposed?"

Sexual relationships4,7

"Is your sexual partner(s) new or long term? Are you and your partner(s) in an open relationship?"

In one survey (n=3652), 68% of HIV transmissions stemmed from the patient’s main partner

When prescribing DESCOVY FOR PrEP®, consider the following3:

  • DESCOVY FOR PrEP should be prescribed only to individuals who are confirmed to be HIV-1 negative immediately prior to initial use and who do not have signs or symptoms consistent with acute HIV infection

  • While using DESCOVY FOR PrEP, HIV-1 screening tests should be repeated at least every 3 months and upon diagnosis of any STIs

  • Individuals must strictly adhere to the dosing schedule because the effectiveness of DESCOVY FOR PrEP is strongly correlated with adherence

  • Use DESCOVY for HIV-1 PrEP to reduce the risk of HIV as part of a comprehensive prevention strategy to reduce the risk of STIs

Take an active role—be the connection between appropriate patients at risk of HIV and the initiation of a PrEP medication.

*The study followed patients in San Francisco, CA.

PCP=primary care physician; STI=sexually transmitted infection.